GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BSP:LILY34) » Definitions » Cyclically Adjusted PB Ratio

Eli Lilly and Co (BSP:LILY34) Cyclically Adjusted PB Ratio : 66.09 (As of May. 02, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PB Ratio?

As of today (2024-05-02), Eli Lilly and Co's current share price is R$135.49. Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was R$2.05. Eli Lilly and Co's Cyclically Adjusted PB Ratio for today is 66.09.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:LILY34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.09   Med: 8.07   Max: 63.61
Current: 63.61

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PB Ratio was 63.61. The lowest was 4.09. And the median was 8.07.

BSP:LILY34's Cyclically Adjusted PB Ratio is ranked worse than
99.39% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.8 vs BSP:LILY34: 63.61

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Eli Lilly and Co's adjusted book value per share data for the three months ended in Mar. 2024 was R$2.238. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$2.05 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PB Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.17 13.64 22.03 28.80 46.99

Eli Lilly and Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.87 36.73 42.35 46.99 63.71

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PB Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Eli Lilly and Co's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=135.49/2.05
=66.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Eli Lilly and Co's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.238/129.4194*129.4194
=2.238

Current CPI (Mar. 2024) = 129.4194.

Eli Lilly and Co Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.200 100.560 1.544
201409 1.237 100.428 1.594
201412 1.219 99.070 1.592
201503 1.408 99.621 1.829
201506 1.373 100.684 1.765
201509 1.787 100.392 2.304
201512 1.705 99.792 2.211
201603 1.676 100.470 2.159
201606 1.513 101.688 1.926
201609 1.531 101.861 1.945
201612 1.423 101.863 1.808
201703 1.326 102.862 1.668
201706 1.407 103.349 1.762
201709 1.412 104.136 1.755
201712 1.157 104.011 1.440
201803 1.453 105.290 1.786
201806 1.352 106.317 1.646
201809 1.678 106.507 2.039
201812 1.204 105.998 1.470
201903 0.327 107.251 0.395
201906 0.370 108.070 0.443
201909 0.484 108.329 0.578
201912 0.372 108.420 0.444
202003 0.524 108.902 0.623
202006 0.740 108.767 0.881
202009 0.908 109.815 1.070
202012 1.011 109.897 1.191
202103 1.351 111.754 1.565
202106 1.129 114.631 1.275
202109 1.427 115.734 1.596
202112 1.775 117.630 1.953
202203 1.628 121.301 1.737
202206 1.513 125.017 1.566
202209 1.852 125.227 1.914
202212 1.960 125.222 2.026
202303 2.047 127.348 2.080
202306 1.886 128.729 1.896
202309 1.946 129.860 1.939
202312 1.853 129.419 1.853
202403 2.238 129.419 2.238

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (BSP:LILY34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Eli Lilly and Co Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (BSP:LILY34) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (BSP:LILY34) Headlines

No Headlines